Loading…
The La Autoantigen Is a Malignancy-Associated Cell Death Target That Is Induced by DNA-Damaging Drugs
Purpose: To evaluate the La autoantigen as a target for specific monoclonal antibody (mAb) binding in dead cancer cells after use of DNA-damaging chemotherapy. Experimental Design: In vitro studies of La-specific 3B9 mAb binding to malignant and normal primary cells with and without cytotoxic drug t...
Saved in:
Published in: | Clinical cancer research 2007-09, Vol.13 (18), p.5509s-5518s |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c403t-c4185777c0ed33a5a6be294482f5e71fb37ccfcd4c5a288dc9d3707606e6b5683 |
---|---|
cites | cdi_FETCH-LOGICAL-c403t-c4185777c0ed33a5a6be294482f5e71fb37ccfcd4c5a288dc9d3707606e6b5683 |
container_end_page | 5518s |
container_issue | 18 |
container_start_page | 5509s |
container_title | Clinical cancer research |
container_volume | 13 |
creator | Al-Ejeh, Fares Darby, Jocelyn M Brown, Michael P |
description | Purpose: To evaluate the La autoantigen as a target for specific monoclonal antibody (mAb) binding in dead cancer cells after use
of DNA-damaging chemotherapy.
Experimental Design: In vitro studies of La-specific 3B9 mAb binding to malignant and normal primary cells with and without cytotoxic drug treatment were
done using immunoblotting and flow cytometry. Chromatin-binding studies and immunofluorescence detection of γH2AX as a marker
of DNA double-stranded breaks together with 3B9 binding assays were done to measure DNA damage responses. Incorporation of
a transglutaminase 2 (TG2) substrate and TG2 inhibition were studied to measure protein cross-linking in dead cells.
Results: La was overexpressed in human cancer cell lines with respect to normal primary cells. Within 3 h of the DNA-damaging stimulus,
La became chromatin bound when it colocalized with γH2AX. Later, after the stimulus produced cell death, La-specific 3B9 mAb
bound specifically and preferentially in the cytoplasm of dead cancer cells. Moreover, 3B9 binding to dead cancer cells increased
with increasing DNA damage. Both La and 3B9 became cross-linked in dead cancer cells via TG2 activity.
Conclusion: La autoantigen represents a promising cancer cell death target to determine chemotherapy response because its expression
was selectively induced in dead cancer cells after DNA-damaging chemotherapy. |
doi_str_mv | 10.1158/1078-0432.CCR-07-0922 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_19735442</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19735442</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-c4185777c0ed33a5a6be294482f5e71fb37ccfcd4c5a288dc9d3707606e6b5683</originalsourceid><addsrcrecordid>eNpF0E1v0zAYwHELMbEx-AggX9gBKcMvcewcq3RApQ4kVM7WE-dJYpQmw0409dvjqEW72D78Htv6E_KBs3vOlfnCmTYZy6W4r6pfGdMZK4V4RW64UjqTolCv0_m_uSZvY_zDGM85y9-Qa66NVtrIG4KHHuke6GaZJxhn3-FId5ECfYTBdyOM7pRtYpychxkbWuEw0C3C3NMDhA5neuhhXid2Y7O4JOoT3f7YZFs4QufHjm7D0sV35KqFIeL7y35Lfn99OFTfs_3Pb7tqs89czuScVm6U1toxbKQEBUWNosxzI1qFmre11M61rsmdAmFM48pGaqYLVmBRq8LIW3J3vvcpTH8XjLM9-ujSn2HEaYmWl1qqPBcJqjN0YYoxYGufgj9COFnO7NrXru3s2s6mvpZpu_ZNcx8vDyz1EZuXqUvQBD5dAEQHQxtSQR9fXCk4LwqV3Oez633XP_uA1iWJIWBECK63XFpurFKsjPIfEZmQSQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19735442</pqid></control><display><type>article</type><title>The La Autoantigen Is a Malignancy-Associated Cell Death Target That Is Induced by DNA-Damaging Drugs</title><source>Freely Accessible Science Journals - check A-Z of ejournals</source><creator>Al-Ejeh, Fares ; Darby, Jocelyn M ; Brown, Michael P</creator><creatorcontrib>Al-Ejeh, Fares ; Darby, Jocelyn M ; Brown, Michael P</creatorcontrib><description>Purpose: To evaluate the La autoantigen as a target for specific monoclonal antibody (mAb) binding in dead cancer cells after use
of DNA-damaging chemotherapy.
Experimental Design: In vitro studies of La-specific 3B9 mAb binding to malignant and normal primary cells with and without cytotoxic drug treatment were
done using immunoblotting and flow cytometry. Chromatin-binding studies and immunofluorescence detection of γH2AX as a marker
of DNA double-stranded breaks together with 3B9 binding assays were done to measure DNA damage responses. Incorporation of
a transglutaminase 2 (TG2) substrate and TG2 inhibition were studied to measure protein cross-linking in dead cells.
Results: La was overexpressed in human cancer cell lines with respect to normal primary cells. Within 3 h of the DNA-damaging stimulus,
La became chromatin bound when it colocalized with γH2AX. Later, after the stimulus produced cell death, La-specific 3B9 mAb
bound specifically and preferentially in the cytoplasm of dead cancer cells. Moreover, 3B9 binding to dead cancer cells increased
with increasing DNA damage. Both La and 3B9 became cross-linked in dead cancer cells via TG2 activity.
Conclusion: La autoantigen represents a promising cancer cell death target to determine chemotherapy response because its expression
was selectively induced in dead cancer cells after DNA-damaging chemotherapy.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-07-0922</identifier><identifier>PMID: 17875783</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Antibodies, Monoclonal - pharmacology ; Antineoplastic agents ; Antineoplastic Agents - toxicity ; Apoptosis - drug effects ; Apoptosis - physiology ; Autoantigens - immunology ; Autoantigens - metabolism ; Biological and medical sciences ; cell death ; Chromatin - metabolism ; Cisplatin - toxicity ; Cross-Linking Reagents - pharmacology ; DNA Breaks, Double-Stranded - drug effects ; DNA damage ; DNA, Neoplasm - drug effects ; Flow Cytometry ; Fluorescent Antibody Technique ; GTP-Binding Proteins - metabolism ; Histones - metabolism ; Humans ; Immunoblotting ; La/SSB ; Lymphocytes - drug effects ; Medical sciences ; Monocytes - drug effects ; Necrosis ; Neoplasms - genetics ; Neoplasms - metabolism ; Neoplasms - pathology ; Pharmacology. Drug treatments ; Protein Glutamine gamma Glutamyltransferase 2 ; ribonucleoprotein ; Ribonucleoproteins - antagonists & inhibitors ; Ribonucleoproteins - immunology ; Ribonucleoproteins - metabolism ; SS-B Antigen ; transglutaminase ; Transglutaminases - metabolism ; Tumor Cells, Cultured</subject><ispartof>Clinical cancer research, 2007-09, Vol.13 (18), p.5509s-5518s</ispartof><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-c4185777c0ed33a5a6be294482f5e71fb37ccfcd4c5a288dc9d3707606e6b5683</citedby><cites>FETCH-LOGICAL-c403t-c4185777c0ed33a5a6be294482f5e71fb37ccfcd4c5a288dc9d3707606e6b5683</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19211665$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17875783$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al-Ejeh, Fares</creatorcontrib><creatorcontrib>Darby, Jocelyn M</creatorcontrib><creatorcontrib>Brown, Michael P</creatorcontrib><title>The La Autoantigen Is a Malignancy-Associated Cell Death Target That Is Induced by DNA-Damaging Drugs</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Purpose: To evaluate the La autoantigen as a target for specific monoclonal antibody (mAb) binding in dead cancer cells after use
of DNA-damaging chemotherapy.
Experimental Design: In vitro studies of La-specific 3B9 mAb binding to malignant and normal primary cells with and without cytotoxic drug treatment were
done using immunoblotting and flow cytometry. Chromatin-binding studies and immunofluorescence detection of γH2AX as a marker
of DNA double-stranded breaks together with 3B9 binding assays were done to measure DNA damage responses. Incorporation of
a transglutaminase 2 (TG2) substrate and TG2 inhibition were studied to measure protein cross-linking in dead cells.
Results: La was overexpressed in human cancer cell lines with respect to normal primary cells. Within 3 h of the DNA-damaging stimulus,
La became chromatin bound when it colocalized with γH2AX. Later, after the stimulus produced cell death, La-specific 3B9 mAb
bound specifically and preferentially in the cytoplasm of dead cancer cells. Moreover, 3B9 binding to dead cancer cells increased
with increasing DNA damage. Both La and 3B9 became cross-linked in dead cancer cells via TG2 activity.
Conclusion: La autoantigen represents a promising cancer cell death target to determine chemotherapy response because its expression
was selectively induced in dead cancer cells after DNA-damaging chemotherapy.</description><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - toxicity</subject><subject>Apoptosis - drug effects</subject><subject>Apoptosis - physiology</subject><subject>Autoantigens - immunology</subject><subject>Autoantigens - metabolism</subject><subject>Biological and medical sciences</subject><subject>cell death</subject><subject>Chromatin - metabolism</subject><subject>Cisplatin - toxicity</subject><subject>Cross-Linking Reagents - pharmacology</subject><subject>DNA Breaks, Double-Stranded - drug effects</subject><subject>DNA damage</subject><subject>DNA, Neoplasm - drug effects</subject><subject>Flow Cytometry</subject><subject>Fluorescent Antibody Technique</subject><subject>GTP-Binding Proteins - metabolism</subject><subject>Histones - metabolism</subject><subject>Humans</subject><subject>Immunoblotting</subject><subject>La/SSB</subject><subject>Lymphocytes - drug effects</subject><subject>Medical sciences</subject><subject>Monocytes - drug effects</subject><subject>Necrosis</subject><subject>Neoplasms - genetics</subject><subject>Neoplasms - metabolism</subject><subject>Neoplasms - pathology</subject><subject>Pharmacology. Drug treatments</subject><subject>Protein Glutamine gamma Glutamyltransferase 2</subject><subject>ribonucleoprotein</subject><subject>Ribonucleoproteins - antagonists & inhibitors</subject><subject>Ribonucleoproteins - immunology</subject><subject>Ribonucleoproteins - metabolism</subject><subject>SS-B Antigen</subject><subject>transglutaminase</subject><subject>Transglutaminases - metabolism</subject><subject>Tumor Cells, Cultured</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNpF0E1v0zAYwHELMbEx-AggX9gBKcMvcewcq3RApQ4kVM7WE-dJYpQmw0409dvjqEW72D78Htv6E_KBs3vOlfnCmTYZy6W4r6pfGdMZK4V4RW64UjqTolCv0_m_uSZvY_zDGM85y9-Qa66NVtrIG4KHHuke6GaZJxhn3-FId5ECfYTBdyOM7pRtYpychxkbWuEw0C3C3NMDhA5neuhhXid2Y7O4JOoT3f7YZFs4QufHjm7D0sV35KqFIeL7y35Lfn99OFTfs_3Pb7tqs89czuScVm6U1toxbKQEBUWNosxzI1qFmre11M61rsmdAmFM48pGaqYLVmBRq8LIW3J3vvcpTH8XjLM9-ujSn2HEaYmWl1qqPBcJqjN0YYoxYGufgj9COFnO7NrXru3s2s6mvpZpu_ZNcx8vDyz1EZuXqUvQBD5dAEQHQxtSQR9fXCk4LwqV3Oez633XP_uA1iWJIWBECK63XFpurFKsjPIfEZmQSQ</recordid><startdate>20070915</startdate><enddate>20070915</enddate><creator>Al-Ejeh, Fares</creator><creator>Darby, Jocelyn M</creator><creator>Brown, Michael P</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>H94</scope></search><sort><creationdate>20070915</creationdate><title>The La Autoantigen Is a Malignancy-Associated Cell Death Target That Is Induced by DNA-Damaging Drugs</title><author>Al-Ejeh, Fares ; Darby, Jocelyn M ; Brown, Michael P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-c4185777c0ed33a5a6be294482f5e71fb37ccfcd4c5a288dc9d3707606e6b5683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - toxicity</topic><topic>Apoptosis - drug effects</topic><topic>Apoptosis - physiology</topic><topic>Autoantigens - immunology</topic><topic>Autoantigens - metabolism</topic><topic>Biological and medical sciences</topic><topic>cell death</topic><topic>Chromatin - metabolism</topic><topic>Cisplatin - toxicity</topic><topic>Cross-Linking Reagents - pharmacology</topic><topic>DNA Breaks, Double-Stranded - drug effects</topic><topic>DNA damage</topic><topic>DNA, Neoplasm - drug effects</topic><topic>Flow Cytometry</topic><topic>Fluorescent Antibody Technique</topic><topic>GTP-Binding Proteins - metabolism</topic><topic>Histones - metabolism</topic><topic>Humans</topic><topic>Immunoblotting</topic><topic>La/SSB</topic><topic>Lymphocytes - drug effects</topic><topic>Medical sciences</topic><topic>Monocytes - drug effects</topic><topic>Necrosis</topic><topic>Neoplasms - genetics</topic><topic>Neoplasms - metabolism</topic><topic>Neoplasms - pathology</topic><topic>Pharmacology. Drug treatments</topic><topic>Protein Glutamine gamma Glutamyltransferase 2</topic><topic>ribonucleoprotein</topic><topic>Ribonucleoproteins - antagonists & inhibitors</topic><topic>Ribonucleoproteins - immunology</topic><topic>Ribonucleoproteins - metabolism</topic><topic>SS-B Antigen</topic><topic>transglutaminase</topic><topic>Transglutaminases - metabolism</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al-Ejeh, Fares</creatorcontrib><creatorcontrib>Darby, Jocelyn M</creatorcontrib><creatorcontrib>Brown, Michael P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al-Ejeh, Fares</au><au>Darby, Jocelyn M</au><au>Brown, Michael P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The La Autoantigen Is a Malignancy-Associated Cell Death Target That Is Induced by DNA-Damaging Drugs</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2007-09-15</date><risdate>2007</risdate><volume>13</volume><issue>18</issue><spage>5509s</spage><epage>5518s</epage><pages>5509s-5518s</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Purpose: To evaluate the La autoantigen as a target for specific monoclonal antibody (mAb) binding in dead cancer cells after use
of DNA-damaging chemotherapy.
Experimental Design: In vitro studies of La-specific 3B9 mAb binding to malignant and normal primary cells with and without cytotoxic drug treatment were
done using immunoblotting and flow cytometry. Chromatin-binding studies and immunofluorescence detection of γH2AX as a marker
of DNA double-stranded breaks together with 3B9 binding assays were done to measure DNA damage responses. Incorporation of
a transglutaminase 2 (TG2) substrate and TG2 inhibition were studied to measure protein cross-linking in dead cells.
Results: La was overexpressed in human cancer cell lines with respect to normal primary cells. Within 3 h of the DNA-damaging stimulus,
La became chromatin bound when it colocalized with γH2AX. Later, after the stimulus produced cell death, La-specific 3B9 mAb
bound specifically and preferentially in the cytoplasm of dead cancer cells. Moreover, 3B9 binding to dead cancer cells increased
with increasing DNA damage. Both La and 3B9 became cross-linked in dead cancer cells via TG2 activity.
Conclusion: La autoantigen represents a promising cancer cell death target to determine chemotherapy response because its expression
was selectively induced in dead cancer cells after DNA-damaging chemotherapy.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>17875783</pmid><doi>10.1158/1078-0432.CCR-07-0922</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1078-0432 |
ispartof | Clinical cancer research, 2007-09, Vol.13 (18), p.5509s-5518s |
issn | 1078-0432 1557-3265 |
language | eng |
recordid | cdi_proquest_miscellaneous_19735442 |
source | Freely Accessible Science Journals - check A-Z of ejournals |
subjects | Antibodies, Monoclonal - pharmacology Antineoplastic agents Antineoplastic Agents - toxicity Apoptosis - drug effects Apoptosis - physiology Autoantigens - immunology Autoantigens - metabolism Biological and medical sciences cell death Chromatin - metabolism Cisplatin - toxicity Cross-Linking Reagents - pharmacology DNA Breaks, Double-Stranded - drug effects DNA damage DNA, Neoplasm - drug effects Flow Cytometry Fluorescent Antibody Technique GTP-Binding Proteins - metabolism Histones - metabolism Humans Immunoblotting La/SSB Lymphocytes - drug effects Medical sciences Monocytes - drug effects Necrosis Neoplasms - genetics Neoplasms - metabolism Neoplasms - pathology Pharmacology. Drug treatments Protein Glutamine gamma Glutamyltransferase 2 ribonucleoprotein Ribonucleoproteins - antagonists & inhibitors Ribonucleoproteins - immunology Ribonucleoproteins - metabolism SS-B Antigen transglutaminase Transglutaminases - metabolism Tumor Cells, Cultured |
title | The La Autoantigen Is a Malignancy-Associated Cell Death Target That Is Induced by DNA-Damaging Drugs |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T04%3A39%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20La%20Autoantigen%20Is%20a%20Malignancy-Associated%20Cell%20Death%20Target%20That%20Is%20Induced%20by%20DNA-Damaging%20Drugs&rft.jtitle=Clinical%20cancer%20research&rft.au=Al-Ejeh,%20Fares&rft.date=2007-09-15&rft.volume=13&rft.issue=18&rft.spage=5509s&rft.epage=5518s&rft.pages=5509s-5518s&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-07-0922&rft_dat=%3Cproquest_cross%3E19735442%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c403t-c4185777c0ed33a5a6be294482f5e71fb37ccfcd4c5a288dc9d3707606e6b5683%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=19735442&rft_id=info:pmid/17875783&rfr_iscdi=true |